Toggle light / dark theme

Nikola Tesla was an inventor who obtained around 300 patents[1] worldwide for his inventions. Some of Tesla’s patents are not accounted for, and various sources have discovered some that have lain hidden in patent archives. There are a minimum of 278 patents[1] issued to Tesla in 26 countries that have been accounted for. Many of Tesla’s patents were in the United States, Britain, and Canada, but many other patents were approved in countries around the globe.[2] Many inventions developed by Tesla were not put into patent protection.

It’s an intruiging technology. All it takes to set up is burying a sensor in the plant’s dirt, and it works for living and non-living things alike. Given that the experience is going to be wildly different depending on the plant, it’s not like this would be useful for doing anything with accuracy. But for doing weird, unique things (while fondling plants) it’s perfect.


In this era of Kinect, Wii, and Leap, everyone wants to capitalize on motion control. Disney still likes physical peripherals, like houseplants for example.

Inaugural Academy for Health and Lifespan Research (AHLR) …towards achieving the goal of not just accelerating longevity research, but making sure that its implications are accessible to all…”


The Academy is comprised of an elite group of world-renowned researchers, scientists and clinicians, all united toward making breakthroughs in longevity both accelerated & accessible.

Turn.bio is based on the scientific breakthrough work at Stanford of Vittorio Sebastiano, Jay Sarkar, and Marco Quarta. They are now leading the team to develop therapies that return mature differentiated cells to a dramatically younger state leaving their differentiated identity unaltered. Congrats!

More info on kizoo.com/en

Two important developers of the celebrated Crispr gene-editing technology said they will make it easier for researchers to license their intellectual property, a move aimed at hastening innovation in the burgeoning field.

MilliporeSigma, the life-sciences tools division of German pharmaceutical giant Merck KGaA, and the Broad Institute of MIT and Harvard said researchers will be able to get nonexclusive rights to patents held by both organizations for research purposes with a single license.

Companies will have to pay a licensing fee. Nonprofit and academic institutions will be permitted to license the patents for free, the organizations said in a news release on Thursday.